Select Bibliography

Filter by any of these (after searching):

There are 224 items

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8)

Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80802

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - AFT-19

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance)

Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009

Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver

Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147

Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849

Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849

Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902

Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset.

Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441

Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance])

Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0591

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104

Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies

Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720

Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance)

Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1

Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - GI - A021202

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581

Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - GI - C9581

Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer.

Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-79-41-51 , NCCTG-83-41-51

Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071

Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance).

Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574

ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer

Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N0026 , NCCTG-N9741

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - C40601

Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392)

Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0392

Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)

Chen, RC , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, M ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9831

Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52

Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).

D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103

Is there a role for older-patient-specific trials? a pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715)

Dao, Dyda , Zelma, Tyler , Jatoi, Aminah , Freedman, Rachel ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151715 , C8541 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741 , N89-30-52 , N9831

Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001

Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001

Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)

Demichele, A. , Dunn, L. , Gimotty, P. , Livasy, C. , Perou, C. ... - ASCO - J Clin Oncol - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007

Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance)

Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503

Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma

Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102

Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901

Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901

Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials.

Dueck, A. , Sargent, D. , Novotny, P. , Decker, P. , Nelson, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - N0591

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203

Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)

Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803

Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC)

Federico Innocenti , Lenz, Heinz-Josef , Meyerhardt, Jeffrey ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

Feldman, D , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, MJ ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials

Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601

Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Fernando, H. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Molecular Subtypes and Response to Neoadjuvant Chemotherapy in TNBC: Results from Brightness Phase III Study AFT-04 (Alliance)

Filho, Otto Metzger , Stover, Daniel , Asad, Sarah , Ansell, Peter ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - AFT-04

Comparative nocebo findings in older patients enrolled in cancer therapeutic trials: observations from a 446-patient cohort (Alliance A151602)

Foster, Jared C. , Le-Rademacher, Jennifer G. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151602 , ACOSOG-Z9001 , NCCTG-97-24-51

Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527

Freedman, Rachel A , Seisler, Drew K. , Foster, Jared C. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101

Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80101

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side.

Furchtgott, Leon , Swanson, David , Hayete, Boris , Khalil, Iya ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Galanis, Evanthia , Anderson, S. Keith , Anastasiadis, Panagiotis Z. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0872

NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Galanis, Evanthia , Anderson, S. Keith , Butowski, Nicholas ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N1174

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)

George, Daniel.J. , Halabi, Susan , Nixon, Andrew B. , Starr, Mark D. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-90206

Ten-Year Survival Results of ACOSOG Z0011 (Alliance)

Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance)

Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N1048

Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)

Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Meta-Analysis Analysis - Breast - CALGB-40601 , CALGB-40603

Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer

Goodman, Karyn A. , Hall, Nathan , Bekaii-Saab, Tanios , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2018

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80803

Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience

Gordon, David , Liu, Qianying , Kleinman, Benjamin ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Health Outcome - Comprehensive

Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)

Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091105

New lesions vs. growth of existing disease: does it impact prognosis?

Grothey, A. , Heun, J. M. , Branda, M. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C

Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - N054C

Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance)

Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Halabi, S. , Kelly, W. K. , Kaplan, E. B. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

Halabi, S. , Ou, S. , Vogelzang, N. J. , Scher, H. I. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - Comprehensive

The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.

Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - GU - CALGB-90401 , S9916

A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy

Halabi, Susan , Lin, Chen-Yen , Small, Eric J. , Armstrong, Andrew J. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).

Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Breast - N0733

Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy

Halyard, M. Y. , Tan, A. D. , Callister, M. D. , Ashman, J. B. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - NCCTG-89-20-52

Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy

Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405

Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)

Hensing, Thomas , Wang, Xiaofei , Kozono, David , Dudek, Arkadius ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-09

A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance)

Hertz, D. L. , Owzar, K. , Halabi, S. , Kelly, W. K. , Zembutsu, H. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - PPP - CALGB-60404 , C90401

A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).

Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - PPP - CALGB-60404 , CALGB-90401

Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG).

Hillman, SL , Sargent, DJ , Bot, BM , RP, DeMatteo , Perez, EA ... - ASCO - J Clin Oncol - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - ACOSOG-Z9001

CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

Himelstein, Andrew L. , Qin, Rui , Novotny, Paul J. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - CALGB-70604

Alliance A091104: A Phase II Trial of MK-2206 in patients with progressive, recurrent/metastatic adenoid cystic carcinoma

Ho, Alan L , Foster, Nathan R. , Meyers, Jeffrey P. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091104

Alliance A091404: a phase II study of enzalutamide (nsc# 766085) for patients with androgen receptor positive salivary cancers

Ho, Alan Loh , Foster, Nathan R. , Zoroufy, Alex J. , Worden, Francis ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091404

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Myeloma - CALGB-100104

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Innocenti, Federico , Ou, Fang-Shu , Zemla, Tyler ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80405

A Genome-Wide Association Study (GWAS) Of Survival In Metastatic Breast Cancer (MBC) Patients Treated With Letrozole (L) With Or Without Bevacizumab (B) In CALGB 40503 (Alliance)

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40503

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572

NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)

Jaeckle, K. , Schiff, D. , Anderson, S. , Galanis, E. , Stella, P. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0572

Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials

Jatoi, A. , Foster, N. R. , Egner, J. , Burch, P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - N064C

A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101

Jelinek, Michael J. , Foster, Nathan R. , Zoroufy, Alex J. ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091101

Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B cell lymphoma (DLBCL): NCCTG N1085 (Alliance) phase I and feasibility study

Johnston, Patrick B. , LaPlant, Betsy R. , Nowakowski, Grzegorz S. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - N1085

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.

Katz, Matthew H.G. , Shi, Qian , Ahmad, Syed , Herman, Joseph ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - GI - A021101

Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

Katz, Matthew , Herman, Joseph M. , Ou, Fang-Shu , Marsh, Robert ... - ASCO - J. Clin. Oncol. - 2017

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GI - A021501

Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

Kelly, W. K. , Halabi, S. , Carducci, M. A. , George, D. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Kent, M. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer

Kim, G. P. , Foster, N. R. , Haddock, M. G. , Dakhil, S. R. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - GI - N064A

Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma

Kim, G. P. , Foster, N. R. , Salim, M. , Flynn, P. J. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - N064B

Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemicitabine (GEM) in patients with unresectable pancreatic cancer

Kim, G. P. , Haddock, M. , Foster, N. R. , Bollinger, J. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - N0349

Phase II of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

Kim, G. P. , Oberg, A. L. , Foster, N. R. , Jaslowski, A. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - N034A

Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).

Klepin, Heidi D. , Ritchie, Ellen K. , Sanford, Ben L. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Older Adult - CALGB-361006

Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206

Kluger, Harriet M. , Halabi, Susan , Solomon, Nicole C ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90206

Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831

Knutson, K. L. , Perez, E. A. , Ballman, K. , Erskine, C. L. , Fox, N. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer

Knutson, Keith L. , Clynes, Raphael , Yeramian, Patrick ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - N0337 , N98-32-52 , N0938

Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).

Kozono, David E. , Salama, Joseph Kamel , Stinchcombe, Tom ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-07

Veliparib (Vel) in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) (AFT-07).

Kozono, David E. , Stinchcombe, Thomas , Salama, Joseph K. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-07

Increasing Adherence to Adjuvant Hormone Therapy among Breast Cancer Patients: A Smart Phone App-Based Pilot Study

Krok-Schoen, Jessica L. , Naughton, Michelle J. , Young, Gregory S. ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - Pilot

Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance)

Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80701

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer

Kutteh, L.A.. , Hobday, T. J. , Jaffe, A. S. , Laplant, B. R. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study

Laack, N. N. , Galanis, E. , Leinweber, C. , Buckner, J. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0877

Randomized Placebo-Controlled Phase II Study of Dasatinib with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (GBM), N0877

Laack, Nadia , Galanis, Eva , Anderson, S. Keith , Leinweber, Clinton ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0877

Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib

Lafky, J. M. , Bot, B. M. , Morlan, B. W. , Anderson, S. K. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C

Association Between Patient Perception of Oncology Clinical Trial Participation and Survival: NCCTG N0392 (Alliance)

Le-Rademacher, Jennifer , Dueck, Amylou , Chauhan, Cynthia ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Health Outcome - NCCTG-N0392

Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405

Identifying Risk Factors For Toxicity In Patients With Hormone-Receptor Positive Advanced Breast Cancer Treated With Bevacizumab Plus Letrozole: A CALGB 40503 (Alliance) Correlative Study

Li, Daneng , Dickler, Maura N. , McCall, Linda M. , Hahn, Olwen M ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-40503

Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance)

Ligibel, J. A. , Cirricione, C. , Liu, M. , Citron, M. , Ingle, J. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Disparities - C9741

The Breast Cancer Weight Loss (BWEL) Trial: Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer (Alliance A011401)

Ligibel, Jennifer A. , Barry, William T. , Alfano, Catherine ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011401

Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes

Liotta, L. , Pierobon, M. , Wulfkuhle, J. , Laird, J. , Livasy, C. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007

Randomized phase II study comparing the met inhibitor cabozantinib to temozolomide (tmz) or dacarbazine (dtic) in ocular melanoma - A091201

Luke, Jason J. , Allred, Jacob B. , Horvath, Laura E. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091201

A randomized phase ii study of anti-PD-1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605)

Luke, Jason , Chmura, Steven , Salama, Joseph , Al-Hallaq, Hania ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Experimental - A091605

Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

Mahoney, M. R. , Sloan, J. A. , Hubbard, J. M. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147

Are actual tumor measurements or categorical tumor response status better at predicting overall survival in cancer clinical trials?

Mandrekar, M. D. , Hillman, S. L. , Campbell, M. E. , Hobbs, B. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741

Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer

Mandrekar, S. , Hillman, S. , Jatoi, A. , Jett, J. , Schild, S. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer

Mandrekar, Sumithra J. , Foster, Nathan R. , Qi, Yingwei ... - ASCO - J. Clin. Oncol. - 2012

Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Respiratory - N0424

Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts)

Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Paschka, P. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20202 , CALGB-9621

A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old

Marcucci, G. , Moser, B. K. , Blum, W. G. , Stock, W. , Wetzler, M. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10201

Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Martin, Miguel , Loibl, Sibylle , Hyslop, Terry ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40503

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Martin, Peter , Jung, Sin-Ho , Johnson, Jeffrey L. , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50803

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104

Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203

Mcleod, H. L. , Owzar, K. , Kroetz, D. L. , Innocenti, F. , Das, S. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80203

Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial

Mcwilliams, R. R. , Mahoney, M. R. , Marchello, B. T. , Jatoi, A. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - GI - N0543

A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.

Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203

Meyerhardt, J. A. , Jackson, N. A. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203

Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114

Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Benson, A. B., 3rd ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - C9081

Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important

Mittendorf, E. , Ballman, K. , Mccall, L. , Hansen, N. , Lucci, A. ... - ASCO - Cancer Res. - 2012

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study

Molina, J. R. , Dy, G. K. , Foster, N. R. , Ziegler, Allen ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Respiratory - N0626

A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study

Molina, J. R. , Mandrekar, S. J. , Dy, G. , Aubry, M. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - N0923

N0937 (Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC)

Moreno-Aspitia, A. , Liu, H. , Hillman, D. , Rowland, K. M. Jr ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - N0937

Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer

Moreno-Aspitia, Alvaro , Holmes, Eileen , Jackisch, Christian ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Morris, Michael J. , Heller, Glenn , Bryce, Alan , Armstrong, Andrew ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - A031201

Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim.

Moukharskaya, Julia , Abrams, Deborah Michelle , Khan, Farrah B. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCT01311336

Standard chemotherapy vs capecitabine for older women with early-stage breast cancer: Long-term results of CALGB 49907 (Alliance)

Muss, Hyman B. , Berry, Donald A. , Cirrincione, Constance T. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-49907

Quality of life (QOL) and toxicity among patients in CALGB 80405

Naughton, M. J. , Schrag, D. , Venook, A. P. , Niedzwiecki, D. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - C80405

Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147)

Newcomb, Polly A. , Sun, Wei , Hua, Xinwei , Banbury, Barbara ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - PPP - NCCTG-N0147

Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance)

Ng, Kimmie , Venook, Alan P. , Sato, Kaori , Yuan, Chen ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)

Nixon, A. B. , Halabi, S. , Shterev, I. , Starr, M. D. , Brady, J. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - GU - C90206

Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405

Nixon, Andrew B. , Sibley, Alexander B. , Hatch, Ace J. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405

Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735

Northfelt, D. W. , Dueck, A. C. , Flynn, T. P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Breast - N0735

Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/Alliance

Nowakowski, Grzegorz S. , LaPlant, Betsy , Macon, William R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - N1088

LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin CALGB 80402

Ocean, A. J. , Niedzwiecki, D. , Atkins, J. N. , Parker, B. A. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80402

Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance)

Ollila, D. , Berry, D. , Cirrincione, C. , Carey, L. , Amos, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - C40601

Correlates of overall survival (OS) in metastatic vs. primary uveal melanoma (UM) and results of a randomized trial of cabozantinib (cabo) vs. chemotherapy (chemo) Alliance A091201

Olson, Daniel J. , Bao, Riyue , Allred, Jacob B. , Strand, Carrie A. ... - ASCO - J Clin Oncol - 2019

Abstract - Secondary Endpoint - Primary Analysis - Experimental - A091201

Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance)

Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N08CB

NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes

Park, Haeseong , Qin, Rui , Smith, Thomas J. , Atherton, Pamela J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C2

Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study

Paschka, P. , Radmacher, M. D. , Marcucci, G. , Ruppert, A. S. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , C9022 , CALGB-19808 , CALGB-8461 , CALGB-9222 , CALGB-9621 , CALGB-9665

Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance).

Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology)

Penney, Kathryn , Banbury, Barbara L. , Shi, Qian ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - N0147

The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831

Perez, E. , Butler, S. , Dueck, A. , Baehner, F. , Jamshidian, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831

Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147

Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - GI - N0147

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Piccart-Gebhart, Martine J. , Holmes, Andrew Peter , Baselga, Jose ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Breast - N063D

Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapic trial

Pockaj, B. A. , Dueck, A. , Tenner, K. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance)

Polite, B. N. , Allred, J. B. , Rugo, H. S. , Cipriano, T. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Disparities - C40502

Tolerability and Toxicity of Trastuzumab or Trastuzumab + Lapatinib in Older Patients

Ponde, Noam Falbel , Agbor-Tarh, Dominique , Lago, Lissandra Dal ... - ASCO - JCO - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials

Qi, Y. , Dy, G. K. , Nelson, G. D. , Schild, S. E. , Mandrekar, S. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Quality of Life Analysis of N0877 (Alliance): Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Qin, Rui , Tan, Angelina D. , Sloan, Jeff A. , Johnson, Derek Richard ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0877

Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE)

Ready, N. E. , Pang, H. H. , Gu, L. , Otterson, G. A. , Thomas, S. P. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - C30504

Effect of IGFIR protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial

Reinholz, M. M. , Dueck, A. L. , Chen, B. , Geiger, X. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Rosenberg, Jonathan , Ballman, Karla , Halabi, Susan , Watt, Colleen ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90601

A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-Induced Neuropathy (NCCTG N08C1, N08CB/Alliance)

Ruddy, Kathryn Jean , Pachman, Dierdre , Qin, Rui , Seisler, Drew K. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - A151505 , N08C1 , N08CB

A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

Ruppert, Amy S. , Byrd, John C. , Heerema, Nyla A. , Smith, Mitchell ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10404

Serum Androgens and Survival in metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel and Prednisone: Results from CALGB 90401 (Alliance)

Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens

Salama, A. K. , Kratzke, R. A. , Richards, W. , Pang, H. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Preliminary Analysis - Correl Sci NOS - CALGB-150607

Clinical trial participants' strategies for coping with prescription drug costs: A companion study to CALGB 80405

Schrag, D. , Naughton, M. J. , Kesselheim, A. , Archer, L. E. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - C80405

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.

Schrag, Deborah , Dueck, Amylou C. , Naughton, Michelle Joy ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - CALGB-70502 , CALGB-80405

Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147

Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147

Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.

Shah, Mithun Vinod , Wiktor, Anne E. , Meyer, Reid G. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831

A model-based approach to dose optimization of neurotoxic chemotherapy drugs for metastatic breast cancer (MBC)

Sharma, Manish , Gray, Elizabeth , Mehrotra, Shailly , Wu, Kehua ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - CALGB-40502

Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database.

Shi, Q. , Hubbard, J. M. , Yothers, G. A. , Andre, T. , Saltz, L. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0441

Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance)

Shi, Qian , Sobrero, Alberto , Shields, Anthony , Yoshino, Takayuki ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80702

Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration

Shields, Anthony F. , Ou, Fang-Shu , Paul, James ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80702

Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101

Shulman, L. , Berry, D. , Cirrincione, C. , Becker, H. , Perez, E. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - C40101

Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer, N1031 Alliance.

Sideras, K. , Moreno-Aspitia, A. , Tenglin, R. C. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N1031

CALGB/Alliance 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) (+/- carboplatin (Cb) and bevacizumab (Bev)) in triple-negative breast cancer (TNBC)

Sikov, William M , Polley, Mei-Yin C , Twohy, Erin L ... - ASCO - J Clin Oncol - 2019

Abstract -